BARDA’s Anthrax Medical Countermeasure Strategy and Portfolio

For over a decade, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) has developed a comprehensive, portfolio approach to the development of medical countermeasures to prevent, reduce the severity of, and treat anthrax infections. 

BARDA uses cutting-edge technologies and works through public-private partnerships to continually improve our ability to respond to an anthrax event. BARDA and other components of the medical countermeasure enterprise are constantly refining their portfolios in accordance with the strategic planning efforts of the Public Health Emergency Medical Countermeasures Enterprise to ensure that their portfolios are comprised of the best available medical countermeasures to protect the American people.